Biomea Fusion (BMEA) risk factors
Item 1A of every Biomea Fusion, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors96 risks4 new14 dropped19 reworded
Biomea Fusion added new operational disclosures covering pandemics, public company employee counts, and ESG compliance. The company clarified its competitive positioning in irreversible covalent menin binders and resolved a Nasdaq audit committee deficiency by appointing Julianne Averill.
Filed Mar 24, 2026 - FY2024 10-K risk factors106 risks
Biomea Fusion is a clinical-stage biotech focused on covalent inhibitors like icovamenib and BMF-500 for diabetes and obesity. The company faces a going concern risk, zero revenues, and a June 2024 FDA clinical hold. Heavy reliance on the unproven FUSION System and intense capital needs dominate its risk profile.
Filed Mar 31, 2025